Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Hims & Hers Health (NYSE:HIMS) has outperformed the market over the past 5 years by 14.14% on an annualized basis producing an average annual return of 25.67%. Currently, Hims & Hers Health has a market

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...

Hims & Hers Health (NYSE: HIMS) shares are climbing after Barclays reiterated its bullish stance and lifted its price target from $29 to $39.

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher on Tuesday as the stock continues to rebound from recent profit-taking.

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

This telehealth stock has fallen hard, but its GLP-1 shift and global expansion could reshape the long-term story. Is the market too skeptical or still too optimistic?

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

The healthcare industry is ripe for disruption.

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

Shares of Hims & Hers Health Inc (NYSE: HIMS) are trading higher Wednesday morning after insider stock purchase boosts investor confidence.

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Raising debt increases the risk in Hims & Hers' stock.

Hims & Hers Health (NYSE: HIMS) shares are trading flat in Tuesday's pre-market as traders continue to digest its convertible notes offering.

Hims & Hers Health’s first quarter was marked by a significant strategic pivot in its weight loss business, which management described as a move to prioritiz...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims & Hers Health (NYSE:HIMS) and its peer...

Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.

The stock continues to be very volatile.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year.

Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608.1 mill...